Gujarat Themis Biosyn Ltd

Stage 2 · Advancing · week 6Setup 3.4 WatchEven +0.8

As of 16 Oct 2026, Gujarat Themis Biosyn is in Stage 2 — advancing, the uptrend phase, in week 6 (since 9 Sep 2026). It closed at ₹373, 20.5% below its 52-week high and above its 200-day average, which is falling. In Health Care, 40.0% of stocks are in Stage 2.

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. More about the company

₹373.4
+0.91% today
₹4,860 Cr · Small cap
Market Neutral — FadingHealth Care 40.0% in Stage 2-7.4 pts / 20dPharmaceuticals 49.6%-2.5 pts

Pro read

Pro

Our read

Early entry — still early enough in its move

Setup score

3.4 Watch

Momentum

Steady

Edge

Even +0.8

Setup-score rank among Stage 2 peers: #53 of 59 in Pharmaceuticals · #63 of 70 in Health Care

Is GUJTHEM early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-20.5%
₹226.9 lo₹469.9 hi
20.5% below 52W high — deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 6
1w13w26w
Week 6 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
3.3%
200 DMA: ₹361.5 · sloping down
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.33x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -6.2% vs MA50 +2.9%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-9.5%
3M
+1.0%
6M
+22.9%
YTD
-8.3%
1Y
-8.6%
Sector
Health Care
↓ Peaking
Stage 2%
40.0%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
This stock ranks #55 of 66 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
49.6%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #46 of 56 Stage 2 stocks in this industry.
Stage Cycle Timeline2025-02-25 → 2026-10-16
S? 42w
S3 8w
S4 11w
S1 7w
2025-02-252026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S2 1w → S3 8w → S4 11w → S1 7w → S2 6w → S3 5w → S2 5w current
Total tracked: 85 weeks across 8 stage runs.
Scan Membership
Prop Scan
Latest: 2026-09-29
Breakout Watch
Latest: 2026-09-09
24 appearances in last 60 days. First seen: 2025-12-17.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-16S2
Wk 6 · Vol 0.33x
2026-10-15S2
Wk 5 · Vol 0.29x
2026-10-14S2
Wk 5 · Vol 1.05x
2026-10-13S2
Wk 5 · Vol 0.72x
2026-10-12S2
Wk 5 · Vol 0.61x
2026-10-09S2
Wk 5 · Vol 0.90x
2026-10-08S2
Wk 4 · Vol 0.55x
2026-10-07S2
Wk 4 · Vol 0.64x
2026-10-06S2
Wk 4 · Vol 0.53x
2026-10-05S2
Wk 4 · Vol 0.40x
2026-10-01S2
Wk 4 · Vol 0.96x
2026-09-30S2
Wk 3 · Vol 0.46x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹394.8
200 DMA
₹361.5
52W High
₹469.9
52W Low
₹226.9
5D Low
₹370.1
Resistance levels (recent highs)
20d High
₹427.4
60d High
₹453.3
120d High
₹453.3
250d High
₹469.9
Next resistance
+14.5%
to 20d High
Ask the Market AI about GUJTHEMAsk →
P/E (TTM)
98.7
Forward —
Earnings Growth (YoY)
-9.1%
Revenue +19.7%
ROE
+17.4%
Profit margin +27.7%
Dividend Yield
0.18%
P/B 17.8
About this companyHealth Care· Pharmaceuticals

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.